QLS-111-FDC for Glaucoma

(Firecrest Trial)

Overseen By Lisa Brandano

Age: Any Age

Sex: Any

Trial Phase: Phase 2 & 3

Sponsor: Qlaris Bio, Inc.

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

60 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free \[PF\], fixed-dose combination \[FDC\] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Who Is on the Research Team?

Barbara M Wirostko, MD

Principal Investigator

Qlaris Bio, Inc.

Are You a Good Fit for This Trial?

Inclusion Criteria

My eye pressure is 19 mmHg or higher after using PF latanoprost.

I have been diagnosed with mild to moderate open-angle glaucoma or ocular hypertension.

BCVA 1.0 logMAR or better in each eye (equivalent to 20/200)

Exclusion Criteria

I have had serious eye diseases, not just mild or moderate glaucoma or high eye pressure.

I have used topical prostaglandin eye drops without much improvement.

Central corneal thickness in either eye <470 or >630 μm

What Are the Treatments Tested in This Trial?

Interventions

• Latanoprost
• QLS-111-FDC

How Is the Trial Designed?

Group I: QLS-111-FDC ophthalmic solution Experimental Treatment 1 Intervention

QLS-111-FDC, PF FDC

Group II: Latanoprost ophthalmic solution Active Control 1 Intervention

PF latanoprost 0.005%

Who Is Running the Clinical Trial?

Qlaris Bio, Inc.

Lead Sponsor

Trials

7

Recruited

250+